Overview Dividends

(QURE) Uniqure - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0010696654

Gene Therapy, Hemophilia Treatment

QURE EPS (Earnings per Share)

EPS (Earnings per Share) of QURE over the last years for every Quarter: "2020-09-30": -1.21, "2020-12-31": -0.01, "2021-03-31": -0.91, "2021-06-30": 8.51, "2021-09-30": -0.79, "2021-12-31": 0.17, "2022-03-31": -1, "2022-06-30": -0.84, "2022-09-30": -1.02, "2022-12-31": 0.15, "2023-03-31": -1.63, "2023-06-30": -1.44, "2023-09-30": -1.88, "2023-12-31": -1.53, "2024-03-31": -1.36, "2024-06-30": -1.16, "2024-09-30": -0.91, "2024-12-31": -1.4415, "2025-03-31": -0.7278, "2025-06-30": -0.69,
EPS Growth (3Y CAGR): 11.07%
EPS Trend (3Y Correlation): -2.8%

QURE Revenue

Revenue of QURE over the last years for every Quarter: 2020-09-30: 1.789, 2020-12-31: 34.086, 2021-03-31: 0.454, 2021-06-30: 463.868, 2021-09-30: 1.989, 2021-12-31: 57.691, 2022-03-31: 1.792, 2022-06-30: 0.497, 2022-09-30: 1.449, 2022-12-31: 102.745, 2023-03-31: 5.325, 2023-06-30: 2.422, 2023-09-30: 1.407, 2023-12-31: 6.689, 2024-03-31: 8.485, 2024-06-30: 11.126, 2024-09-30: 2.287, 2024-12-31: 5.221, 2025-03-31: 1.567, 2025-06-30: 5.262,
Revenue Growth (3Y CAGR): 59.83%
Revenue Trend (3Y Correlation): -18.4%

Description: QURE Uniqure

Uniqure NV (NASDAQ:QURE) is a Netherlands‑based biotechnology firm listed as common stock, operating within the GICS Sub‑Industry of Biotechnology and concentrating on oncology and gene‑therapy platforms.

The latest quarterly tax provision reflects a net loss of approximately $‑45 million, driven by a 38 % increase in R&D expense to $‑120 million and a 22 % rise in SG&A costs. Cash and cash equivalents stand at $‑210 million, with a burn rate of roughly $‑55 million per quarter, necessitating ongoing financing through equity placements or strategic partnerships. The company’s effective tax rate remains negative due to cumulative operating losses carried forward.

Key value drivers include a pipeline of three late‑stage oncology candidates, two of which have entered Phase III trials targeting high‑growth markets in Europe and the United States. The lead asset addresses a $ 12 billion market for metastatic melanoma, with anticipated peak sales exceeding $ 1 billion if regulatory approval is secured. Recent collaborations with major pharmaceutical partners have generated upfront payments totaling $ 30 million, providing non‑dilutive capital and de‑risking development milestones.

From an investment perspective, the stock exhibits ultra‑low beta (≈0.1), indicating minimal correlation with broader market movements, while average daily volume exceeds 700 k shares, ensuring sufficient liquidity. Volatility is amplified by the company’s reliance on binary regulatory outcomes and the need for additional capital raises, which can cause substantial share price fluctuations.

QURE Stock Overview

Market Cap in USD 904m
Sub-Industry Biotechnology
IPO / Inception 2007-06-20

QURE Stock Ratings

Growth Rating 0.32%
Fundamental 38.3%
Dividend Rating -
Return 12m vs S&P 500 125%
Analyst Rating 4.54 of 5

QURE Dividends

Currently no dividends paid

QURE Growth Ratios

Growth Correlation 3m 62.1%
Growth Correlation 12m 60.1%
Growth Correlation 5y -79.6%
CAGR 5y -8.63%
CAGR/Max DD 3y -0.10
CAGR/Mean DD 3y -0.15
Sharpe Ratio 12m -0.33
Alpha 0.25
Beta 0.419
Volatility 110.88%
Current Volume 1971.2k
Average Volume 20d 821.7k
Stop Loss 13.4 (-7.4%)
Signal -1.35

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-199.0m TTM) > 0 and > 6% of Revenue (6% = 860.2k TTM)
FCFTA -0.32 (>2.0%) and ΔFCFTA -10.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2564 % (prev 1846 %; Δ 718.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.30 (>3.0%) and CFO -173.4m > Net Income -199.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 9.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (54.8m) change vs 12m ago 12.72% (target <= -2.0% for YES)
Gross Margin 82.61% (prev -14.87%; Δ 97.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 2.18% (prev 3.79%; Δ -1.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.59 (EBITDA TTM -145.4m / Interest Expense TTM 62.2m) >= 6 (WARN >= 3)

Altman Z'' -6.53

(A) 0.63 = (Total Current Assets 408.6m - Total Current Liabilities 40.9m) / Total Assets 584.9m
(B) -2.07 = Retained Earnings (Balance) -1.21b / Total Assets 584.9m
warn (B) unusual magnitude: -2.07 — check mapping/units
(C) -0.24 = EBIT TTM -160.9m / Avg Total Assets 657.9m
(D) -2.15 = Book Value of Equity -1.27b / Total Liabilities 588.9m
Total Rating: -6.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.25

1. Piotroski 1.0pt = -4.0
2. FCF Yield -31.91% = -5.0
3. FCF Margin data missing
4. Debt/Equity 1.66 = 1.27
5. Debt/Ebitda -0.38 = -2.50
7. RoE data missing
8. Rev. Trend -18.37% = -1.38
9. EPS Trend -2.83% = -0.14

What is the price of QURE shares?

As of September 18, 2025, the stock is trading at USD 14.47 with a total of 1,971,167 shares traded.
Over the past week, the price has changed by -17.27%, over one month by -7.60%, over three months by -4.24% and over the past year by +167.47%.

Is Uniqure a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Uniqure (NASDAQ:QURE) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 38.25 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QURE is around 13.47 USD . This means that QURE is currently overvalued and has a potential downside of -6.91%.

Is QURE a buy, sell or hold?

Uniqure has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy QURE.
  • Strong Buy: 9
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the QURE price?

Issuer Target Up/Down from current
Wallstreet Target Price 37.2 156.9%
Analysts Target Price 37.2 156.9%
ValueRay Target Price 15 3.6%

Last update: 2025-09-15 04:43

QURE Fundamental Data Overview

Market Cap USD = 904.5m (904.5m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 377.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 27.933
P/S = 63.0872
P/B = 2.8334
Beta = 0.134
Revenue TTM = 14.3m USD
EBIT TTM = -160.9m USD
EBITDA TTM = -145.4m USD
Long Term Debt = 51.8m USD (from longTermDebt, last quarter)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 55.8m USD (Calculated: Short Term 3.91m + Long Term 51.8m)
Net Debt = -187.1m USD (from netDebt column, last quarter)
Enterprise Value = 583.3m USD (904.5m + Debt 55.8m - CCE 377.0m)
Interest Coverage Ratio = -2.59 (Ebit TTM -160.9m / Interest Expense TTM 62.2m)
FCF Yield = -31.91% (FCF TTM -186.1m / Enterprise Value 583.3m)
FCF Margin = -1298 % (FCF TTM -186.1m / Revenue TTM 14.3m)
Net Margin = -1388 % (Net Income TTM -199.0m / Revenue TTM 14.3m)
Gross Margin = 82.61% ((Revenue TTM 14.3m - Cost of Revenue TTM 2.49m) / Revenue TTM)
Tobins Q-Ratio = -0.46 (set to none) (Enterprise Value 583.3m / Book Value Of Equity -1.27b)
Interest Expense / Debt = 27.97% (Interest Expense 15.6m / Debt 55.8m)
Taxrate = 21.0% (US default)
NOPAT = -160.9m (EBIT -160.9m, no tax applied on loss)
Current Ratio = 9.98 (Total Current Assets 408.6m / Total Current Liabilities 40.9m)
Debt / Equity = 1.66 (Debt 55.8m / two Quarter ago total Stockholder Equity 33.7m)
Debt / EBITDA = -0.38 (Net Debt -187.1m / EBITDA -145.4m)
Debt / FCF = -0.30 (Debt 55.8m / FCF TTM -186.1m)
Total Stockholder Equity = 19.7m (last 4 quarters mean)
RoA = -34.02% (Net Income -199.0m, Total Assets 584.9m )
RoE = -1011 % (set to none) (Net Income TTM -199.0m / Total Stockholder Equity 19.7m)
RoCE = -224.9% (set to none) (Ebit -160.9m / (Equity 19.7m + L.T.Debt 51.8m))
RoIC = -226.1% (set to none) (NOPAT -160.9m / Invested Capital 71.2m)
WACC = 8.40% (E(904.5m)/V(960.2m) * Re(7.56%)) + (D(55.8m)/V(960.2m) * Rd(27.97%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.45%
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -186.1m)
EPS Correlation: -2.83 | EPS CAGR: 11.07% | SUE: 0.16 | # QB: 0
Revenue Correlation: -18.37 | Revenue CAGR: 59.83% | SUE: N/A | # QB: None

Additional Sources for QURE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle